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https://doi.org/10.1016/j.jaci.2019.10.033Objective: We sought to assess the risk of HL associated with
allergic disease (asthma, eczema, and allergic rhinitis) and
corticosteroid use.
Methods: We conducted a case-control study using the
United Kingdom Clinical Practice Research Datalink
(CPRD) linked to hospital data. Multivariable logistic
regression investigated associations between allergic diseases
and HL after adjusting for established risk factors. Potential
confounding or effect modification by steroid treatment were
examined.
Results: One thousand two hundred thirty-six patients with HL
were matched to 7416 control subjects. Immunosuppression was
associated with 6-fold greater odds of HL (adjusted odds ratio
[aOR], 6.18; 95% CI, 3.04-12.57), with minimal change after
adjusting for steroids. Any prior allergic disease or eczema alone
was associatedwith 1.4-fold increased odds ofHL (aOR, 1.41 [95%
CI, 1.24-1.60] and 1.41 [95% CI, 1.20-1.65], respectively). These
associations decreased but remained significant after adjustment
for steroids (aOR, 1.25 [95% CI, 1.09-1.43] and 1.27 [95% CI,
1.08-1.49], respectively). There was no effect modification by
steroid use. Previous steroid treatmentwas associatedwith 1.4-fold
greater HL odds (aOR, 1.38; 95% CI, 1.20-1.59).
Conclusions: In addition to established risk factors
(immunosuppression and infectious mononucleosis), allergic
disease and eczema are risk factors for HL. This association is
only partially explained by steroids, which are associated with1
Abbreviations used
aOR: Adjusted odds ratio
CPRD: Clinical Practice Research Datalink
HES: Hospital Episode Statistics
HL: Hodgkin lymphoma
ICD-10: International Classification of Diseases, 10th revision
IM: Infectious mononucleosis
IMD: Index of multiple deprivation
OR: Odds ratio
SES: Socioeconomic status
TYAs: Teenagers and young adults
UK: United Kingdom
UTS: Up to standard
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2 RAFIQ ET ALincreased HL risk. These findings add to the growing evidence
that immune system malfunction after allergic disease or
immunosuppression is central to HL development. (J Allergy
Clin Immunol 2019;nnn:nnn-nnn.)
Key words: Allergic disease, Hodgkin lymphoma, corticosteroids,
asthma, eczema, allergic rhinitis, risk, atopic dermatitis
Hodgkin lymphoma (HL) is a cancer of the lymphatic system
and is the most common cancer in teenagers and young adults
(TYAs) worldwide.1,2 A number of conditions with disordered
immune regulation have been associated with an increased risk
of HL in TYAs. These include infectious mononucleosis (IM)
after EBV infection,3-7 HIV infection,8-10 immunosuppressive
therapy,11-17 and several autoimmune diseases, such as multiple
sclerosis,18 systemic lupus erythematosus,19 and rheumatoid
arthritis.20,21 Certain HLA genes that are responsible for
regulation of the immune system in human subjects have also
been associated with increased risk of HL in genetic studies.22,23
These findings together provide support for immune system
malfunction playing a central role in the development of HL.
The antigenic stimulation hypothesis has been suggested to
explain the underlying mechanism for immune systemmalfunction
in HL development. It proposes that conditions with chronic
immune stimulation predispose subjects to hematologic malig-
nancies, such as multiple myeloma, non-HL, and leukemia, by
promoting development of randomly occurring pro-oncogenic
mutations in actively dividing immune cells.24-26 There is a growing
body of evidence supporting this hypothesis and showing that a
number of immune-related cancers, including leukemia, occur as a
consequence of immune system malfunction in early life.27-29
Allergic diseases, including asthma, eczema, and allergic
rhinitis, are among the most common perpetrators of chronic
immune stimulation. Few studies have investigated the link
between allergic diseases and HL, and the results have been
conflicting and inconclusive.24,25,30-35 Previous studies have been
small scale or relied on small numbers of exposed subjects and
therefore might not have had the power to detect associations.
No studies have been conducted using electronic health records
from primary care, in which allergic disease is predominantly
diagnosed and managed, or in the United Kingdom (UK)
population, which has one of the highest rates of both HL in
TYAs and allergic disease worldwide.36,37
Corticosteroids are a mainstay in the treatment of allergic
diseases. Their use is often reserved for more severe cases that
have not responded to first-line conventional therapies, and they
act primarily through suppression of the immune response.
Therefore any association between allergic disease and HL could
be intertwined with the effects of steroids: steroid use could
modify any effect (because they are a marker of allergic disease
severity) or confound it (because they are used in treatment of a
range of immune-related diseases that might also be risk factors
for HL). Therefore it is important to consider this interplaying
role in any study of allergic disease. Some studies have identified
steroids as a risk factor for lymphoma,38-40 although others have
found no increased risk41,42; more importantly, it is unclear
whether steroid use is an independent risk factor, a marker of
allergic disease severity, or a proxy for other immune-related
diseases. Furthermore, many of the studies did not differentiate
between the types of lymphoma or focused only on topicalsteroids, adding to the uncertainty surrounding the role of steroid
treatment and HL risk.
In this study we used linked primary care electronic health
records to determine whether subjects with a history of allergic
disease (asthma, eczema, or allergic rhinitis) are at a greater risk
of HL in earlier life and whether HL risk varied according to
steroid exposure.METHODS
Study design and setting
We conducted a matched case-control study using data from the UK
Clinical Practice Research Datalink (CPRD), which is linked to Hospital
Episode Statistics (HES) inpatient data and index of multiple deprivation
(IMD) data. CPRD is an electronic health record database containing
prospectively collected anonymized data from UK primary care
consultations. It is the largest source of longitudinal primary care data,
holding information on 22 million patients, representing approximately 9%
of the UK population (in 2013).43 Data are available from 1987 onward,
when CPRD was first established. It contains information on clinical
symptoms, diagnoses (coded using Read codes), investigation results,
medications, and referrals to specialists. Practices contributing to CPRD
are regularly audited to ensure high data quality and that 95% of prescribing
and morbidity events are captured before practices are declared ‘‘up to
standard’’ (UTS) for research purposes.43
CPRD data used in this studywere enhanced by prelinkage toHES. TheHES
database contains records from every attendance at a National Health Service
hospital in England (approximately 125 million episodes per year). Each
episode consists of clinical information on diagnoses, procedures, and past
medical history coded in International Classification of Diseases, 10th revision
(ICD-10). Data are available from April 1997 for patients in practices that have
consented to data linkage (54%of all contributing CPRDpractices in the UK).44
CPRD data were additionally prelinked to information on quintiles of IMD
scores in practices that had consented to data linkage. These can be considered
to represent a composite ecological (small area–based) measure of the
socioeconomic status (SES) of a patient based on the income, employment,
disability, educational attainment, and other attributes of the Local Super
Output Area of a postcode. The latter typically comprise populations of
between 1000 and 3000 residents. All patients had an aggregate IMD score
pertaining to the Local Super Output Area in which their general practice is
located. For this study, datawere extracted from the July 2016CPRDbuild and
the Set 13 linked data.Study population
HL has a bimodal age-specific incidence pattern, with the first peak
occurring at between 15 and 34 years of age.45 Subjects aged 50 years or less
whowere actively registered with a CPRD practice that hadUTS data between
FIG 1. Directed acyclic graph for the study. Solid lines indicate assumed associations from previous studies,
and dashed lines indicate proposed associations examined in the current analysis.
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were excluded if they had an HL diagnosis before entry into the study to avoid
inclusion of retrospectively recorded past/prevalent cases, if they had no re-
corded IMD status, and if they had follow-up of less than 1 year in CPRD.
Defining cases with HL. All subjects in the study population with
a first diagnosis of HL aged 50 years or less in either CPRD or HES during the
study period were included as potential cases (see Table E1 in this article’s
Online Repository at www.jacionline.org for Read and ICD-10 code lists).
The earliest recorded date of diagnosis was taken as the index date. Cases
were excluded if the diagnosis was made within 1 year of registering with a
CPRD practice (in accordance with previous studies to ensure that only
incident HL diagnoses were identified)46 or if there was no event date for
the HL diagnosis.
Defining matched control subjects. Six control subjects for
each case were selected using individual matching on age at index date
(61 year), sex, and duration of active follow-up time (62 years). A matched
design was an efficient way to deal with the potential contributing effects of
these variables. Concurrent sampling was used to match HL cases to control
subjects who were HL free at the index date of the case while being under
active follow-up in a UTS CPRD practice with a similar length of follow-up
time before the index date. These subjects could not have an HL diagnosis at
the time ofmatching (index date) but could go on to haveHL in the future. This
method allowed ‘‘matching on time’’ with cases in this dynamic population.47
Each control subject was assigned an index date corresponding to the date of
diagnosis of their matched case.
Defining patients with allergic disease. A diagnosis of
allergic disease was defined as a coded diagnosis of asthma, eczema, or
allergic rhinitis in CPRD or HES at any point before the index date. Because
we are interested in both incident and prevalent cases of allergic disease,
subjects with a diagnosis at any point in their medical record before the index
date were classed as having an allergic disease (see Table E2 in this article’s
Online Repository at www.jacionline.org for Read and ICD-10 code lists). The
total number of allergic diseases (with a maximum of 3) and the date and ageof first reporting of allergic disease diagnosis were recorded (categorized as
infant [<1 year], child [1-17 years], or adult [>_18 years] onset).
Defining corticosteroid use. Corticosteroid use was defined as
coded use of any corticosteroid (subclassified as inhaled, topical, oral or
intravenous/intramuscular) in CPRD at any point more than 6 months before
the index date (see Table E3 in this article’s Online Repository at
www.jacionline.org for the code list). A ‘‘lag time’’ of 6 months before the
index date was used in line with previous studies to reduce the possibility of
reverse causality in the months immediately before HL diagnosis because
early symptoms of undiagnosed HL might lead to steroid treatment in the
period leading up to the diagnosis.48 Steroid use was further classified by
the frequency of use during follow-up (total number of coded issues before
6 months before index date).
Covariates and mediators. We used a directed acyclic graph to
inform the identification of potential covariates and mediators and to avoid
collider bias (Fig 1). Covariates included the matched variables of age, sex,
and follow-up time and SES (by using quintiles of 2010 IMD). A prior
diagnosis of IM or immunosuppressive conditions were also included based
on a recorded diagnosis in HES or CPRD before the index date because these
are established risk factors for HL. For IM, codes for EBV infection, positive
laboratory test results, and IM caused by other viruses were included
(see Table E4 in this article’s Online Repository at www.jacionline.org).
When classifying immunosuppression, congenital, acquired, and iatrogenic
causes were included (see Table E5 in this article’s Online Repository at
www.jacionline.org for code lists).Statistical analysis
Primary analyses. We initially described the baseline characteristics
of cases and control subjects. Univariable conditional logistic regression
(matched on age at index date, sex, and follow-up duration) was used to
generate odds ratios (ORs) for the association between each of the exposure
variables and HL, followed by multivariable conditional logistic regression
TABLE I. Baseline characteristics of patients with HL and control subjects
Characteristics Patients with HL (n 5 1236) Control subjects (n 5 7416) P value*
Mean years of follow-up (SD [range]) 6.03 (5.00 [0.01-26.42]) 6.01 (4.96 [0.00-26.87]) .9
Male sex 702 (56.8%) 4212 (56.8%) 1.00
Age at start of follow-up (y) .98
0-10 208 (16.8%) 1265 (17.1%)
11-20 241 (19.5%) 1396 (18.8%)
21-30 357 (28.9%) 2129 (28.7%)
31-40 331 (26.8%) 2026 (27.3%)
41-50 99 (8.0%) 600 (8.1%)
Age at index date (y) 1.00
0-10 35 (2.8%) 210 (2.8%)
11-20 239 (19.3%) 1434 (19.3%)
21-30 337 (27.3%) 2002 (27.3%)
31-40 355 (28.7%) 2129 (28.7%)
41-50 270 (21.8%) 1621 (21.9%)
IMD quintile .09
5 (most deprived) 251 (20.3%) 1598 (21.6%)
4 277 (22.4%) 1641 (22.1%)
3 246 (19.9%) 1442 (19.4%)
2 221 (17.9%) 1325 (17.9%)
1 (least deprived) 241 (19.5%) 1410 (19.0%)
Immunosuppression 16 (1.3%) 15 (0.2%) <.001
IM 43 (3.5%) 131 (1.8%) <.001
Allergic disease 500 (40.5%) 2429 (32.8%) <.001
Steroid use 731 (59.1%) 3714 (50.1%) <.001
Inhaled 294 (23.8%) 1548 (20.9%) .02
Topical 604 (48.9%) 3011 (40.6%) <.001
Oral 110 (8.9%) 449 (6.1%) <.001
Intravascular/intramuscular 30 (2.4%) 112 (1.5%) .02
No. of steroids <.001
0 505 (40.9%) 3702 (49.9%)
1 201 (16.3%) 1178 (15.9%)
>_2 530 (42.9%) 2536 (34.2%)
Median no. of steroids (IQR) 1 (0-4) 1 (0-3) <.001
IQR, Interquartile range.
*P value from x2 test or Mann-Whitney U test for continuous variables.
Matched variables.
Defined as diagnosis of asthma and/or eczema and/or allergic rhinitis during the follow-up period.
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subsequently introduced to investigate potential effect modification of the
association between HL incidence and allergic disease by age, sex, and SES.
A further analysis was conducted on the final regression model,
categorizing allergic disease as a linear rather than binary variable to take
into account the number of allergic diagnoses. We assessed for linear trend by
number of allergic diagnoses, first by estimating the linear effect using
likelihood ratio tests and then by investigating departure from linearity by
comparing models in which allergic disease was added as a nonlinear versus a
linear term. We used 95% CIs and an implied 5% level of statistical
significance to minimize the risk of a type 1 error.
We repeated the analyses with alternative exposure definitions in which
each allergic disease was considered separately. First, we constructed a cross-
tabulation comparing the frequency of combinations of allergic diseases in
cases and control subjects. Then we repeated the conditional logistic
regression analysis described above, with asthma, eczema, and allergic
rhinitis included as separate variables to evaluate their independent effect on
HL incidence after adjusting for each other and other variables in the model.
Interaction terms were introduced to investigate for potential effect modifi-
cation of the estimated risk associated with each allergic disease by age, sex,
and SES strata and also other allergic disease. In supplementary analyses, for
each of the 3 allergic diseases separately, using likelihood ratio tests, we
examined whether a model in which they were categorized as infant/
childhood/adult onset differed from a model in which they were considered
as yes-no variables independent of age of onset. Where there was evidence for
heterogeneity, stratum-specific adjusted odds ratios (aORs) were estimated.Secondary analyses. A secondary analysis was conducted incor-
porating steroid use into the final model to assess for potential effect
modification when stratifying by steroid use and to investigate the extent to
which the effect of variables might be confounded by steroid treatment by
comparing effect estimates before and after adjustment for steroid use. The
effect of steroids was also assessed before and after adjustment for other
variables, both collectively (any steroid use) and stratified by route of
administration (inhaled, topical, oral, or intravenous/intramuscular). We
assessed for a potential dose-response relationship by estimating the linear
effect of number of steroid prescriptions before the index date on HL risk and
by route of administration (ordered according to strength/level of systemic
absorption) using likelihood ratio tests, as described above.
Sensitivity analysis. A sensitivity analysis was performed restricted
to subjects with HES-linked data, and effect estimates were compared with
estimates of the whole case-control population. Analyses were performed with
Stata software (version 15; StataCorp, College Station, Tex).
Ethics approval and consent to participate
The protocol for this project was approved by the London School of
Hygiene and Tropical Medicine Ethics Committee (reference 11182) and the
Independent Scientific Advisory Committee for MHRA Database Research
(protocol no. 16_237). Generic ethical approval for observational studies
conducted with anonymized CPRD data with approval from Independent
Scientific Advisory Committee has been granted from a National Research
Ethics Service Committee. The study was performed in accordance with the
Declaration of Helsinki.
TABLE II. Frequency of concurrent allergic diseases: Proportion of cases and control subjects with a diagnosis of 1 or more
allergic conditions
Asthma Eczema Allergic rhinitis All 3
Concurrent allergic diagnoses in cases (n 5 1236)
Asthma 18.9% (233) 6.6%(82) 4.6% (57)
Eczema 6.6% (82) 21.0% (260) 4.4% (55)
Hay fever 4.6% (57) 4.4%(55) 13.9% (172)
All 3 2.4% (29)
Concurrent allergic diagnoses in control subjects (n 5 7416)
Asthma 15.2% (1129) 4.4% (323) 4.2% (308)
Eczema 4.4% (323) 15.6% (1154) 3.2% (241)
Hay fever 4.2% (308) 3.2% (241) 12.4% (918)
All 3 1.4% (100)
P value* .001 <.001 .13
*P value for x2 test comparing allergic disease in cases and control subjects.
TABLE III. Association between exposures and HL incidence (<_50 years)
Variable Univariable OR (95% CI) aOR* (95% CI) OR after adjustment for steroids (95% CI)
Immunosuppression 6.36 (3.15-12.87) 6.18 (3.04-12.57) 6.05 (2.97-12.33)
P value <.001 <.001 <.001
IM 2.00 (1.41-2.84) 1.89 (1.33-2.68) 1.87 (1.31-2.67)
P value <.001 <.001 .001
Allergic disease 1.42 (1.25-1.62) 1.41 (1.24-1.60) 1.25 (1.09-1.43)
P value <.001 <.001 .002
Deprivation quintile
5 (most deprived) Reference Reference Reference
4 1.08 (0.89-1.29) 1.09 (0.90-1.30) 1.08 (0.90-1.30)
3 1.09 (0.90-1.32) 1.08 (0.89-1.31) 1.07 (0.89-1.30)
2 1.06 (0.87-1.29) 1.05 (0.86-1.28) 1.04 (0.86-1.27)
1 (least deprived) 1.09 (0.90-1.32) 1.06 (0.88-1.29) 1.05 (0.87-1.28)
P value .47 .69 .75
Steroid use 1.51 (1.33-1.72) 1.38 (1.20-1.59) —
P value <.001 <.001 —
*Matched on age, sex, and follow-up time and adjusted for other variables in the model (region, deprivation, immunosuppression, atopy, and IM); P values were from the likelihood
ratio test.
P value for test for linear trend.
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There were 1236 incident cases of HL in this study
individually matched to 7416 control subjects. Table I shows
the baseline characteristics of subjects in the case-control
sample. Mean follow-up time was 6 years. Cases were more
likely to be immunosuppressed (1% vs 0.2%), have a history
of IM (4% vs 2%), and have a diagnosis of at least 1 of the 3
allergic diseases (41% vs 33%, Table I). Treatment with steroids
was more commonly seen in cases than in control subjects for all
routes of administration, with significantly more cases having 2
or more steroid prescriptions during follow-up when compared
with control subjects (43% vs 34%, P < .001; Table I).
Cross-tabulation of combinations of allergic diseases showed
increased prevalence of asthma (19% vs 15%), eczema (21%
vs 16%), and asthma and eczema combined (7% vs 4%) in cases
compared with control subjects (Table II). Distribution of all
other exposure variables did not differ substantially between
cases and control subjects (Table I).Immunosuppression
Immunosuppression was by far the strongest risk factor for HL
incidence in this study. Immunosuppressed subjects had 6 times
greater odds of HL on univariable analysis (P < .001). There wasvery little change in OR after adjusting for other variables,
indicating the effect was independent of SES, allergic disease,
and IM (aOR, 6.18; 95% CI, 3.04-12.57; P < .001). A slight
attenuation in OR was noted after adjusting for steroid use
(aOR, 6.05; 95% CI, 2.97-12.33; P < .001), indicating that part
of the effect of immunosuppression on HL risk might be
attributable to steroid use (Table III).IM
IM was associated with double the odds of HL on univariable
analysis (P <.001). There was minimal attenuation of the effect in
mediation models after adjusting for immunosuppression, SES,
and allergic disease (aOR, 1.89; 95% CI, 1.33-2.68; P < .001)
and negligible change in the OR after adjusting for steroid use
(Table III). This indicates the effect of IM on HL is independent
of these variables.Allergic disease
A previous diagnosis of 1 or more allergic diseases was
associated with 1.4-fold greater odds of HL (P < .001), with
minimal change after adjusting for other variables (aOR, 1.41;
95% CI, 1.24-1.60; P < .001; Table III). The risk of HL increased
TABLE IV. Association between atopic diseases and HL incidence (<50 years)
Variable Univariable OR aOR* OR after adjustment for steroids
Asthma 1.31 (1.11-1.53) 1.23 (1.04-1.45) 1.15 (0.97-1.36)
P value .001 .016 .11
Eczema 1.47 (1.26-1.72) 1.41 (1.20-1.65) 1.27 (1.08-1.49)
P value <.001 <.001 .005
Allergic rhinitis 1.15 (0.96-1.37) 1.06 (0.88-1.27) 0.99 (0.83-1.19)
P value .13 .56 .94
Immunosuppression 6.36 (3.15-12.87) 6.05 (2.98-12.30) 5.94 (2.91-12.10)
P value <.001 <.001 <.001
IM 2.00 (1.41-2.84) 1.88 (1.32-2.68) 1.87 (1.31-2.66)
P value <.001 <.001 .001
Steroid use 1.51 (1.33-1.72) 1.39 (1.21-1.60) —
P value <.001 <.001 —
Topical steroid 1.46 (1.28-1.66) 1.34 (1.17-1.54) —
P value <.001 <.001 —
Inhaled steroid 1.20 (1.03-1.39) 1.03 (0.87-1.23) —
P value .017 .73 —
Oral steroid 1.54 (1.23-1.92) 1.30 (1.02-1.65) —
P value <.001 .036 —
Intravascular/intramuscular steroid 1.63 (1.08-2.46) 1.55 (1.03-2.35) —
P value .019 .037 —
No. of steroids 1.01 (1.00-1.01) 1.00 (1.00-1.01) —
P value .003 .37 —
No. of atopic diseases
0 Reference Reference Reference
1 1.43 (1.24-1.64) 1.42 (1.23-1.63) 1.27 (1.09-1.47)
2 1.30 (1.04-1.63) 1.27 (1.01-1.60) 1.10 (0.87-1.39)
3 2.05 (1.34-3.13) 2.04 (1.34-3.13) 1.75 (1.14-2.68)
P value <.001 <.001 .005
P values were from the likelihood ratio test.
*Matched on age, sex, and follow-up time and adjusted for other variables in the model (SES, immunosuppression, atopic diseases, and IM).
P value for test for linear trend.
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trend < .001, Table IV). When analyzing by specific allergic
disease type, eczema and asthma were associated with increased
risk of HL (aOR 1.41 [95%CI, 1.20-1.65;P <.001] and 1.23 [95%
CI, 1.04-1.45; P 5 .016], respectively) with no evidence of an
association between allergic rhinitis and HL (Table IV).
In a supplementary analysis comparing age of allergic disease
onset, asthma and allergic rhinitis had similar average age of onset
in cases and control subjects. However, for eczema, the median
age of onset was 15 years in control subjects and 20 years in cases
(P5 .004). Relatedly, there were significantly more incidences of
adult-onset eczema among cases than control subjects (54% vs
44%, see Table E6 in this article’s Online Repository at
www.jacionline.org), with strong evidence that the effect of
eczema on HL risk differed according to age of eczema onset
(P 5 .006). Only adult-onset eczema was associated with
increased odds of HL (aOR, 1.73; 95% CI, 1.40-2.13; P < .001;
see Table E7 in this article’s Online Repository at
www.jacionline.org). There was no evidence of heterogeneity
of effect estimates by age of onset for asthma or allergic rhinitis
(P 5 .33 and .27, respectively; data not shown).
In the secondary analysis, after adjusting for steroid use,
associations between allergic disease and eczema with HL were
attenuated but still found to be significant (aOR, 1.25 [95% CI,
1.09-1.43; P 5 .002] and 1.27 [95% CI, 1.08-1.49; P 5 .005],
respectively; Tables III and IV). In asthmatic patients, after adjust-
ment for steroids, there was no increased risk of HL (Table IV).
There was no difference in effect estimates when stratifying bysteroid use (Table V), and there was no evidence of effect modifica-
tion by age at index date, sex, or SES (test for interaction P5 .12,
.063, and .41, respectively; additional analyses not shown in tables).
Corticosteroid use
Previous steroid use for any indication was associated with
increased risk of HL. Subjects with a history of steroid use at any
time before 6 months before the index date had 1.5-fold increased
odds of HL (OR, 1.51; 95% CI, 1.33-1.72; P <.001). All routes of
administration were associated with increased risk, with the
strongest associations seen for intravenous/intramuscular
administration, followed by oral, topical, and then inhaled
steroids (Table IV). After adjusting for other variables, including
allergic disease and other immune conditions, steroid use
remained a significant risk factor for HL development (aOR,
1.38; 95%CI, 1.20-1.59;P <.001), and this was seen for all routes
of administration except inhaled steroids (Table IV).Sensitivity analysis
Restricting the analysis to patients who had HES-linked data
available (59.6% of all patients in this study) produced similar
effect estimates for variables across all regression analyses.DISCUSSION
This study shows that allergic disease and steroid use for any
indication are associated with an increased risk of HL before the
TABLE V. Association between allergic diseases and HL
incidence stratified by steroid use
Variable
Used steroid,
aOR* (95% CI)
Never used
steroids,
aOR* (95% CI)
P value for
effect
modification
Allergic disease 1.17 (0.99-1.37) 1.48 (1.15-1.90)
P value .064 .002 .12
Asthma 1.00 (0.83-1.21) 1.85 (1.34-2.56)
P value .99 <.001 .002
Eczema 1.27 (1.07-1.51) 1.27 (0.81-1.99)
P value .007 .31 .99
Allergic rhinitis 0.96 (0.78-1.18) 1.14 (0.77-1.71)
P value .69 .51 .45
Immunosuppression 9.08 (3.59-22.96) 2.67 (0.71-10.10)
P value <.001 .15 .12
IM 1.82 (1.17-2.83) 1.96 (1.08-3.56)
P value .008 .028 .85
P values were from the likelihood ratio test.
*Matched on age, sex, and follow-up time and adjusted for other variables in the
model (SES, immunosuppression, atopic diseases, and IM).
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RAFIQ ET AL 7age of 50 years. A previous diagnosis of eczema, but not asthma or
allergic rhinitis, is associated with development of HL, with this
effect being concentrated in patients with adult-onset eczema.
This effect does not differ by steroid exposure and persists after
adjustment for steroid use. Previously established risk factors for
HL involving immune dysfunction were also found in this study
to be important risk factors for HL in early life. Immunosup-
pressed subjects had a 6-fold increased odds of HL, and thosewith
a history of IM had almost double the odds.Comparison with the literature
Associations between allergic conditions and HL have been
inconsistent and inconclusive in the literature (see Table E8 in this
article’s Online Repository at www.jacionline.org). S€oderberg
et al25 conducted a Swedish population-based case-control study
of 2394 patients with HL that found asthma was associated with a
40% reduced risk of HL. This study relied on hospital discharge
summary data, which are likely to include only severe asthma,
and results were based on only 18 exposed cases.
Vineis et al30 conducted an Italian population-based
case-control study that reported a 50% reduced risk of HL in
patients with allergic rhinitis but no effect of asthma or eczema.
This was a small study of 354 cases and relied on face-to-face
interviews of adults, which might introduce recall bias of
childhood exposures.
Cozen et al31 carried out a twin study comparing 188 HL-
discordant twin pairs in the United States using questionnaires.
They found that eczema was associated with a 4-fold increased
risk of HL but was based on only 19 discordant pairs for the
exposure.
A number of further studies have concluded no association
between allergic disease and HL risk.24,32-35 These were
small-scale case-control studies of up to 585 cases and relied on
retrospectively collected exposure data from telephone interviews
and questionnaires. Misclassification is therefore likely because of
exposures being self-reported. Additionally, many of the studies
included a diagnosis of HL at any age, which could produce
misleading results because studies have shown HL in subjects
aged less than 50 andmore than 50 years are likely to have different
causes and might even be 2 separate disease entities.49-51Existing studies on steroid use andHL are also limited and have
produced conflicting findings. One study found an increased risk
of any lymphoma with oral steroid use but no increased risk with
topical steroids after adjusting for other factors.39 A second study
focusing specifically on HL found no increased risk, even at
considerable and cumulative doses of oral steroids; however,
this study focused on HL cases aged more than 50 years.41
Some further studies of topical steroid use have shown increased
HL risk in a dose-response fashion, with increasing duration of
exposure and potency,38,40 but others have shown no increased
risk, even with moderate/highly potent topical steroids.42Strengths and limitations
We know of no previous studies assessing the association
between allergic diseases with HL using prospectively collected
population-based primary care electronic health records data and
considering the potential interplay with steroid treatment. CPRD
data are representative of the UK population across a number of
demographic variables,43 which supports the external validity of
the findings. Allergic conditions are predominantly diagnosed
and treated in primary care, making general practitioner electronic
health records an ideal setting for examining them. Recording of
asthma diagnosis in CPRD has high validity against gold standard
diagnosis, with a positive predictive value of 86.4%.52 HL
diagnoses have high validity in CPRD when compared with gold
standard national cancer registration data (positive predictive value
for lymphoma, 89.6%; sensitivity, 97.3%).53 Combined use of
primary and secondary care HES-linked data further improved
the validity of exposures and outcomes by supplementing general
practitioner records with hospital data to improve capture of
diagnoses. We used detailed exploration of diagnostic codes
verified by 2 clinicians and crosschecking with existing code lists
in the literature to further improve diagnostic accuracy. Rates of
allergic diseases and HL in the study population showed a similar
distribution to that reported in the literature. The large study sample
enabled the precise estimation of associations, providing adequate
power to identify associations when the effect size is small.
Prospectively collected data have low risk of recall bias, unlike
other types of data used in previous studies.
As for all observational studies based on routine data, there is
potential for confounding, bias, and missing data. However, the
high degree of concordance of CPRD data with the national
cancer registration means misclassification of HL is likely to be
low in this study, with good capture of cases. CPRD data do not
include staging information, which precluded us exploring
possible variation in effect estimates by stage at diagnosis.
A degree of misclassification and underreporting of allergic
diagnoses is likely, but this nondifferential misclassification
would potentially bias toward the null, meaning that observed
estimates of associations between allergic diseases andHLwill be
conservative. Some patients who will have contracted EBV will
not experience any symptoms leading to consultation, and some
who do will be misdiagnosed. These mechanisms would both
similarly result in potential underestimation of effect estimates
because the 2 comparator groups (cases/control subjects) become
more similar artefactually, and therefore the findings for IM are
likely conservative. Route of steroid administration was used as a
proxy for steroid strength as a marker of a dose-response
relationship (it was not possible to directly estimate cumulative
steroid exposure or exact doses).
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We propose 3 potential explanations for the observed
association between allergic disease and increased HL risk in
early life identified in this study. The first is in support of the
antigenic stimulation hypothesis for HL pathogenesis. Chronic
overactivation of the immune response in patients with allergic
disease over time results in randomly occurring mutations in
rapidly dividing lymphocytes. These might be carcinogenic or
cancer promoting, leading to HL development in predisposed
subjects.
The second explanation is that allergic disease and HL
development in TYAs share a common immune pathway in their
development, and when regulation of this pathway is disrupted, the
risk of subsequently having both conditions increases. Some
studies have proposed the programmed cell death protein 1
receptor pathway and its ligands (programmed death ligands 1
and 2) as a potential culprit because its components have been
linked to both allergic diseases and HL pathogenesis.6,54-58 Further
studies are required to ascertain the presence and components of
common underlying pathways, which, if identified, could present
new targets for therapeutic intervention for these conditions.59
The third explanation is that therapeutic treatment for allergic
diseases, such as steroids, which could themselves affect immunity,
might increase a subject’s risk of having HL either directly or by
increasing the risk of contracting pro-oncogenic infections, such as
EBV. Disruption of the skin barrier in patients with eczema might
also act in this way by increasing access to other viral pathogens.
However, we observed that allergic disease was associated with
increased odds of HL, even after adjusting for steroids and IM
history. Further studies should explore the potential interplay
between eczema, other viral infections, and HL risk.
This study showed that steroid use for any indication is
associated with increased risk of HL in this patient population.
There was evidence of a possible dose-response effect by route of
administration, with routes of higher systemic absorption
associated with greater HL risk. Interestingly, although steroid
use was more frequently observed in cases than in control
subjects, the effect of allergic disease on HL risk did not differ
when stratifying by steroid use. This suggests the effects of
steroids are not due to them being amarker ofmore severe allergic
disease. Additionally, the association with steroids and HL
persisted after adjusting for allergic diseases and other established
risk factors included in the model, indicating their effect is not
fully explained by these conditions. Possible explanations include
that steroids might be an independent risk factor for HL, and this
is a genuine causal association; however, it is more likely that
steroids are a proxy for other immune diseases, which are
independent risk factors for HL and occur more commonly in
allergic subjects in this patient population. Previous studies have
demonstrated evidence for a link between allergic diseases and
other immune conditions in support of this hypothesis.60 Further
studies are required to examine the timing, duration, and
dose-response relationships between steroid exposure and HL
development and the role of other immune diseases to establish
their role in HL development more clearly.Conclusions
This study has identified allergic diseases, specifically eczema,
and steroid use for any indication as risk factors for HL in early
life. This is in addition to the established risk factors ofimmunosuppression and IM, which also cause immune
dysfunction. These findings add to the growing evidence that
immune dysregulation is central to the development of HL in
early life and that allergic disease in childhood might increase the
risk of hematologic malignancies in the future.
This study is based in part on data from the CPRD obtained under license
from the UKMedicines and Healthcare products Regulatory Agency. The data
are provided by patients and collected by theNational Health Service as part of
their care and support. The interpretation and conclusions contained in this
study are those of the author or authors alone. This study was also carried out
as part of the CALIBER program (https://www.ucl.ac.uk/health-informatics/
caliber). CALIBER, led from the UCL Institute of Health Informatics, is a
research resource consisting of anonymized coded variables extracted from
linked electronic health records, methods and tools, specialized infrastructure,
and training and support.
Key messages
d Allergic disease, especially eczema, is associated with
increased risk of HL.
d Corticosteroid treatment is associated with increased HL
risk.
d Immune system malfunction after allergic disease or
immunosuppression is central to HL development.REFERENCES
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